Studies have shown that EGFR-TKIs (erlotinib) and angiogenesis inhibitors that target endothelial growth factor receptor (anti-VEGFR) (bevacizumab) (A + T) achieved superior PFS and acceptable safety in NSCLC patients with intracranial metastasis [24]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.